That sure is a ton of people at 2 years staying off of systemic therapy. Why so few oncologists outside #radonc talk about it bewilders me. Shankar Siva

A/Prof Steven David presenting on ablative treatments (SABR) for oligometastatic breast cancer at #bct2024. A great debate with Prof Prue Francis (medical oncologist)

Assoc Prof Steven David takes to the stage at #bct2024. Expertly discussing oligometastatic #breastcancer and the need for further research of #SABR in this space. Bring on AVATAR-2! Well done, Steven David 👏👏👏 Targeting Cancer RANZCR Peter Mac Cancer Centre BreastCancerTrials

Our soldier Evan Thomas MD/PhD has returned from his tour of duty in Iraq. Thank you for your service brother! 🇺🇸 #radonc

I enjoyed my visit to the GU Cast studio for the recording of the Prostate Cancer Olympics 2024 podcast with Arun Azad , Declan Murphy and Renu Eapen. We had some discrepancies about the gold medalists, which would your winners? GU Cast | Urology podcast! youtu.be/6NqT9z1c8aw?si…

A new study from the UK demonstrates that single-station N2 NSCLC staged by PET/CT and EBUS lymph node sampling is actually multi-station N2 disease in 32-34% of cases. 🇬🇧 Shankar Siva BTOG jtocrr.org/article/S2666-…

Drew Moghanaki 🐕 Shankar Siva BTOG David Baldwin Corinne Faivre-Finn 💙 Fiona McDonald Sanjay Popat Haval Balata Jonathan Spicer MD PhD donington Patrick Forde M.Provencio Really thought provoking. It fits with the staging discordance as reported in the Seismic study led by Daniel Steinfort Shankar Siva and colleagues at Peter Mac Cancer Centre . It’s hard to hit the target when you don’t know where it is…🎯

Pt with met. RCC, oligoprogressive while on IO/TKI - growing primary + new RP LNs. Tx'ed the kidney mass (worst implications if kept growing) w/ PULSAR, q-2 days before IO inf. x3 (TKI held). Fascinating response in the un-tx'ed LN! Robert Timmerman David Sher Shankar Siva

Post hoc analysis of CALGB 140503 just out in JAMA Oncology ➡️reports a poorer outcome for patients with small tumours (<2cm) and visceral pleural invasion (T2) as compared to <2cm ➡️highlights need for adjuvant studies for this subgroup of patients 🔗jamanetwork.com/journals/jamao…

🧵1/6 📜 New study alert! About 25% of patients for curative RT in India have a prior h/o Channel TURP mostly for disease related obstruction. Priyamvada Maitre Maneesh Singh #ProstateCancer #RadiationTherapy #TURP

💥Registration reminder!! wix.to/4EIH3X9 The #SIGA2024 Workshop & COGNO ASM will form the premiere neuro-oncology event in Australasia this year and will be held at Melbourne's Langham Hotel. Program: sigastereotactic.com/workshop/progr… Registration: sigastereotactic.com/workshop/regis…

Simulation-Free Radiation Therapy Check out this excellent podcast from Sue Yom & the #RedJournal IJROBP - The Red Journal, featuring our very own Dr Katrina Woodford, Lead Radiation Therapist Clinician Scientist Peter Mac Cancer Centre. 😃 Well done, Katrina Woodford 👏 Listen here ➡️ redjournal.org/audio-do/red-j…

It appears there is a lack of academic clinical trials being presented at the #WCLC24 Presidential Symposium…similar to what we observed at #ASCO24 Any thoughts on why this might be? #academia IASLC ASCO ESMO - Eur. Oncology

Completely devastated by the loss of our colleague and friend Dr Brian Kelly this week. We have posted a Memorial Session on GU Cast GU Cast | Urology podcast! Renu Eapen youtu.be/skkczjCwSBU

🛑🛑🛑Here is our STOP RCT looking at SABR in patients with oligoprogressive cancers, just published in @ijrobp www-redjournal-org.proxy1.lib.uwo.ca/article/S0360-… We learned a few important lessons for clinical practice and for the design of future trials...(thread 👇)

Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC. How about others? #radonc pubmed.ncbi.nlm.nih.gov/34048817/

Nelson Ferreira Anurag K. Singh Jie Deng, MD PhD Shankar Siva Filippo Alongi Felipe Couñago PhD Here is a reference that might help. sciencedirect.com/science/articl…

Sharing our paper reporting the new indication of SABR for primary kidney cancer. Shankar Siva anna bruynzeel bjui-journals.onlinelibrary.wiley.com/doi/abs/10.111…

New clinical guideline for challenging spine cases. I have the pleasure of working with the leaders in the field! Thanks for the leadership Kristin Redmond Simon Lo Amazing support from arjun sahgal Shankar Siva Matthias Guckenberger Joshua D. Palmer, MD Eric Chang et al

A phase III randomized clinical trial demonstrates improved OS, PFS, and LRC with 4 weeks of hypofx-CRT (3 Gy/d) versus 6 weeks of conventional CRT (2 Gy/d). 🇨🇳 #radonc Sue Yom redjournal.org/article/S0360-…